These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 26238860)

  • 1. Comments Concerning "Comparison of Airway and Systemic Malondialdehyde Levels for Assessment of Oxidative Stress in Cystic Fibrosis".
    Khoubnasabjafari M; Ansarin K; Jouyban A
    Lung; 2015 Oct; 193(5):867-8. PubMed ID: 26238860
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to the Letter Entitled "Comments Concerning Comparison of Airway and Systemic Malondialdehyde Levels for Assessment of Oxidative Stress in Cystic Fibrosis".
    Antus B; Barta I
    Lung; 2015 Oct; 193(5):861-2. PubMed ID: 26283028
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of Airway and Systemic Malondialdehyde Levels for Assessment of Oxidative Stress in Cystic Fibrosis.
    Antus B; Drozdovszky O; Barta I; Kelemen K
    Lung; 2015 Aug; 193(4):597-604. PubMed ID: 25951912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Markers of oxidative damage in blood of children with cystic fibrosis].
    Chełchowska M; Laskowska-Klita T; Nowaczewska I; Narolewska U
    Pol Merkur Lekarski; 2002 Aug; 13(74):123-5. PubMed ID: 12420342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased plasma fatty acid concentrations after respiratory exacerbations are associated with elevated oxidative stress in cystic fibrosis patients.
    Wood LG; Fitzgerald DA; Gibson PG; Cooper DM; Garg ML
    Am J Clin Nutr; 2002 Apr; 75(4):668-75. PubMed ID: 11916752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. beta-Carotene, malondialdehyde, and cystic fibrosis.
    Winklhofer-Roob BM
    Am J Clin Nutr; 1997 Feb; 65(2):575-7. PubMed ID: 9022550
    [No Abstract]   [Full Text] [Related]  

  • 7. Oxidative stress in stable cystic fibrosis patients: do we need higher antioxidant plasma levels?
    Lezo A; Biasi F; Massarenti P; Calabrese R; Poli G; Santini B; Bignamini E
    J Cyst Fibros; 2013 Jan; 12(1):35-41. PubMed ID: 22781546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal study of oxidative status in 312 cystic fibrosis patients in stable state and during bronchial exacerbation.
    Lagrange-Puget M; Durieu I; Ecochard R; Abbas-Chorfa F; Drai J; Steghens JP; Pacheco Y; Vital-Durand D; Bellon G
    Pediatr Pulmonol; 2004 Jul; 38(1):43-9. PubMed ID: 15170872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for increased oxidative damage in patients with cystic fibrosis.
    Brown RK; Kelly FJ
    Pediatr Res; 1994 Oct; 36(4):487-93. PubMed ID: 7816524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Serum and sputum eosinophil cationic protein levels and clinical status in cystic fibrosis patients].
    Korzeniewska A; Sołoniewicz A; Stelmach P; Sobocińska A; Stelmach I
    Pneumonol Alergol Pol; 2006; 74(4):372-6. PubMed ID: 17427145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-8: an important chemoattractant in sputum of patients with chronic inflammatory airway diseases.
    Richman-Eisenstat JB; Jorens PG; Hébert CA; Ueki I; Nadel JA
    Am J Physiol; 1993 Apr; 264(4 Pt 1):L413-8. PubMed ID: 8476069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Purification and characterization of defensins from cystic fibrosis sputum.
    Soong LB; Ganz T; Ellison A; Caughey GH
    Inflamm Res; 1997 Mar; 46(3):98-102. PubMed ID: 9098722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring oxidative stress during chronic obstructive pulmonary disease exacerbations using malondialdehyde.
    Antus B; Harnasi G; Drozdovszky O; Barta I
    Respirology; 2014 Jan; 19(1):74-9. PubMed ID: 23834671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolastin aerosol therapy and sputum taurine in cystic fibrosis.
    Cantin AM; Berthiaume Y; Cloutier D; Martel M
    Clin Invest Med; 2006 Aug; 29(4):201-7. PubMed ID: 16986483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dynamics of markers of blood inflammation against the background of antibacterial therapy in children with mucoviscidosis, with the various regimens of intake of pancreatic enzymes].
    Kashirskaia NIu; Shmarina GV; Kapranov NI; Pukhal'skiĭ AL
    Eksp Klin Gastroenterol; 2004; (2):48-52, 109. PubMed ID: 15462322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sputum and serum calprotectin are useful biomarkers during CF exacerbation.
    Gray RD; Imrie M; Boyd AC; Porteous D; Innes JA; Greening AP
    J Cyst Fibros; 2010 May; 9(3):193-8. PubMed ID: 20299288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidative stress and lipid-derived inflammatory mediators during acute exacerbations of cystic fibrosis.
    Reid DW; Misso N; Aggarwal S; Thompson PJ; Walters EH
    Respirology; 2007 Jan; 12(1):63-9. PubMed ID: 17207027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidative Stress Markers in Sputum.
    Antus B
    Oxid Med Cell Longev; 2016; 2016():2930434. PubMed ID: 26885248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of nutrient absorption may enhance systemic oxidative stress in cystic fibrosis patients.
    Shmarina GV; Pukhalsky AL; Kokarovtseva SN; Pukhalskaya DA; Kalashnikova EA; Kapranov NI; Kashirskaja NJ
    Mediators Inflamm; 2001 Apr; 10(2):61-7. PubMed ID: 11405551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship of clinical and inflammatory markers to outcome in stable patients with cystic fibrosis.
    Downey DG; Martin SL; Dempster M; Moore JE; Keogan MT; Starcher B; Edgar J; Bilton D; Elborn JS
    Pediatr Pulmonol; 2007 Mar; 42(3):216-20. PubMed ID: 17238189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.